Vir Biotechnology stock falls 3.34 percent after Q2 results
Published on 09/25/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vir Biotechnology stock fell 3.34 percent to USD 10.72 on Nasdaq in after-hours trading on September 24, 2026. The move followed a Q2 report that combined unusually high revenue with a major collaboration payment and a clearer clinical timetable.
Q2 revenue beats consensus
Vir reported USD 238.9 million in Q2 2026 revenue, compared with USD 135.88 million expected by analysts, according to The Globe and Mail. The figure was largely driven by recognition of a USD 240 million Astellas upfront payment, while total Astellas payments reached USD 315 million during the quarter.
Net income was USD 80.1 million in Q2 2026, compared with a USD 111.0 million net loss in Q2 2025. Diluted earnings per share came in at USD 0.47, versus USD 0.33 consensus, as reported by MarketBeat.
Clinical milestones set the next test
The financial comparison is powerful but partly payment-driven, so the pipeline remains central to the valuation. In the SOLSTICE study, 88 percent of patients receiving elebsiran plus tobevibart achieved undetectable hepatitis delta virus RNA at week 96, compared with 53 percent receiving tobevibart alone, according to the Q2 2026 earnings-call transcript.
Vir expects top-line data from ECLIPSE 1 in Q4 2026, while ECLIPSE 2 and ECLIPSE 3 are scheduled for Q1 2027. The company also expects updated VIR-5818 dose-escalation data in the second half of 2026, creating several dated checkpoints beyond the one-time Astellas revenue.
Analyst target stays above market
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating and a USD 20 price target on September 22, 2026, according to Moomoo. That target stands USD 9.28 above the September 24 quote, making the analyst view dependent on clinical execution rather than the Q2 payment alone.
Stock remains below yearly high
Vir Biotechnology stock had a market capitalization of USD 1,807,949,161 on September 24, 2026. Its 52-week range was USD 4.82 to USD 11.94, leaving the quote 10.22 percent below the yearly high.
Vir Biotechnology stock facts
- Company: Vir Biotechnology, Inc.
- Ticker: VIR
- Trading venue: Nasdaq
- Price (as of September 24, 2026): USD 10.72 after-hours quote
- Market capitalization: USD 1,807,949,161 (as of September 24, 2026)
- 52-week range: USD 4.82-11.94 (as of September 24, 2026)
- Sector / Industry: Healthcare / Biotechnology
